Navigation Links
Trianni Announces Launch of Its Optimized Human Antibody Transgenic Mouse
Date:9/26/2013

EMERYVILLE, Calif., Sept. 26, 2013 /PRNewswire/ -- Trianni, Inc., a Californian biotechnology company, announced today the launch of its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates.

Monoclonal antibodies are the most successful biologic therapeutics on the market.  More than thirty have been approved for use in humans and hundreds are currently undergoing testing in clinical trials for a broad range of clinical conditions.  Among the options currently available for therapeutic antibody discovery, transgenic mice, such as the Trianni Mouse, are unmatched in their suitability for meeting pharmaceutical research needs.

The Trianni Mouse is an advanced transgenic platform featuring highly engineered antibody genes, generated using state-of-the-art DNA synthesis and genome modification methodology.  It replicates the full antibody-producing capacity – or repertoire – of a human being, and features many enhancements designed to improve its performance as a discovery vehicle.  Trianni's technology represents a significant and highly distinctive advance over existing human antibody transgenic mouse platforms.

The Trianni Mouse platform is now available, with additional variations to follow in the first half of 2014.

Trianni is actively seeking partnerships with interested biotechnology and pharmaceutical companies.  For further information on the technology, please visit trianni.com.

About the Trianni Mouse Antibody Discovery Platform

Trianni took a radically different approach to generating its transgenic mouse platform.  This began with the design and chemical synthesis of novel chimeric antibody 'gene segments' each composed of human antibody-coding information combined directly with mouse regulatory information.  Well over a hundred distinct segments were assembled into large arrays, which were then embedded in the mouse genome in place of their normal mouse counterparts.  The outcome was antibody genes that are optimized for function in the mouse yet nonetheless express a full repertoire of human variable domains.  The Trianni mouse that carries these unique genes is a validated platform ideal for the isolation of therapeutic monoclonal antibodies.

About Trianni

Trianni was formed in 2010 with the sole focus of developing and distributing its optimized antibody discovery platform, The Trianni Mouse. It has been funded throughout from private sources. The company has administrative and research facilities in the San Francisco Bay Area and in Germany, respectively. Its executive team includes academic molecular immunologists and business development personnel with successful track records in biotechnology.

Contact:

Michael Greenberg, Chief Business Officer
Phone: +1 650-530-0640
Email: Michael.greenberg@trianni.com

 


'/>"/>
SOURCE Trianni
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):